Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288465 | 0.83 | LMNA (0.49) | LMNAMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4283529 | 0.80 | FFAR4 (0.40) | LMNAMEN1KMT2AGAA | |
| SCHEMBL4287834 | 0.78 | KDM4E (0.41) | MEN1KMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4287638 | 0.78 | LMNA (0.50) | LMNAMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4297009 | 0.78 | KDM4E (0.47) | MEN1KMT2AALDH1A1 | |
| SCHEMBL4287941 | 0.78 | KDM4E (0.47) | MEN1KMT2AGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL4293729 | 0.77 | MAPK1 (0.41) | LMNAMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4285550 | 0.77 | MEN1 (0.40) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4282070 | 0.77 | NPC1 (0.48) | LMNAMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL4281106 | 0.76 | BTK (0.39) | LMNAGAAALDH1A1POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885MEN1 1254/4885KMT2A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.